RNA Analytical/Quality Videos

  1. Assessing The Quality & Maturity Of The Next-Gen Oligo Supply Chain 12/3/2025

    As our molecules grow more complicated, so, too, does the supply chain. Here, Advancing RNA Live speakers Khaled Yamout & Camp4’s Satya Kuchimanchi talk through how this growth challenges our understanding of raw material quality and how sponsors can better assess their suppliers.

  2. The Strategic Shift(s) In gRNA CMC 4/29/2026

    In this opening Advancing RNA Live clip, panelists Max De Long, April Sena, and Venkat Krishnamurthy share the biggest scientific and manufacturing breakthrough made in the world of gRNA production over the past year. 

  3. The Biggest Challenges In Adopting Enzymatic Ligation of gRNA 4/29/2026

    In this Advancing RNA Live clip, panelists Venkat Krishnamurthy and April Sena home in on the economic, molecular, and biological challenges complicating the transition to enzymatic ligation today. 

  4. Establishing Analytical Methods For Emerging mRNA-Based Therapies 6/5/2023

    Here, we describe the use of cutting-edge technologies to assess critical quality attributes of both mRNA drug substances and drug products.

  5. Improving IVT Processes: Addressing Analytical Limitations & PAT Shortcomings 4/11/2025

    Advancing RNA Live panelists identify what is “as good as we can get right now” in terms of understanding our IVT reactions while sharing their ideas on how we can arrive at a future that includes real-time monitoring of our drug substance production processes.

  6. mRNA/saRNA Manufacturing: Accelerate The Path To Clinic 3/22/2021

    Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.

  7. The Evolving CMC Landscape For mRNA-LNPs 2/24/2026

    In this Advancing RNA Live clip, CMC consultant Sujit Jain unpacks the levels of maturity he’s observed in process and analytical development, as well as supply chain. While vaccines and liver-targeting therapeutics boast what we can call a reproducible platform today, targeted LNP therapies introduce a handful of scale-up sensitivities and characterization hurdles.

  8. Therapeutic Market Opportunities For mRNA 10/16/2023

    In this segment from the Bioprocess Online Live digital event Risk Reduction In mRNA Therapeutic Development, hundreds of audience members tell us what forms of vaccine and therapeutics they’re developing.

  9. In Which Specific Areas Do mRNA Makers Need More Regulatory Guidance? 5/10/2024

    Experts from this Advancing RNA Live panel discuss the results from a poll question revealing the top three areas RNA industry experts would be most interested in seeing additional mRNA-specific guidance from regulatory agencies.

  10. Sustainable Vaccine Manufacturing: Securing The Future Of Global Health 7/22/2025

    Explore how next-gen technologies, from mRNA platforms to digital tools, are transforming vaccine manufacturing to make it more sustainable, flexible, and accessible.